IP Library Granted Patent US 11,168,150
Granted Patent B2
US 11,168,150 · App. 16/665,708 · Granted Nov 9, 2021

T cell receptor-like antibody agents specific for EBV latent membrane protein 2A peptide presented by human HLA

Inventors: Nai-Kong V. Cheung (New York, NY); Mahiuddin Ahmed (Verona, NJ); Andres Lopez-Albaitero (New York, NY); Cheng Liu (Emeryville, CA); Su Yan (State College, PA); Jingyi Xiang (Walnut Creek, CA); Hong Liu (El Sobrante, CA)
Assignees: Memorial Sloan Kettering Cancer Center; Eureka Therapeutics, Inc.
C07K16/468C07K16/085C07K16/2809G01N33/6854A61K2039/505A61K2039/572C07K2317/21C07K2317/31C07K2317/32C07K2317/33C07K2317/34C07K2317/40C07K2317/41C07K2317/56C07K2317/565C07K2317/622C07K2317/732C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,168,150
App. No.
16/665,708
Granted
Nov 9, 2021
Kind
B2
Abstract

Described herein are antibodies, fragments thereof and multi-specific binding agents that bind an Epstein-Barr virus (EBV) latent membrane protein 2 (LMP2) peptide presented by HLA class I molecules, in particular, HLA-A02. Also provided herein are methods of using the same or compositions thereof for the detection, prevention and/or therapeutic treatment of diseases characterized by expression of an EBV-LMP2 peptide presented by HLA-A02, in particular, Burkit's lymphoma, Hodgkin's lymphoma and nasopharyngeal carcinoma.

Claims (61)

1. An isolated nucleic acid molecule encoding a human antibody agent that binds an EBV-LMP2/HLA peptide complex, wherein the human antibody agent comprises:

(a) heavy chain CDR1 of SEQ ID NO:31, heavy chain CDR2 of SEQ ID NO:33, heavy chain CDR3 of SEQ ID NO:35; light chain CDR1 of SEQ ID NO:73, light chain CDR2 of SEQ ID NO:75 and light chain CDR3 of SEQ ID NO:77;

(b) heavy chain CDR1 of SEQ ID NO:37, heavy chain CDR2 of SEQ ID NO:39, heavy chain CDR3 of SEQ ID NO:41, light chain CDR1 of SEQ ID NO:79, light chain CDR2 of SEQ ID NO:81, and light chain CDR3 of SEQ ID NO:83;

(c) heavy chain CDR1 of SEQ ID NO:43, heavy chain CDR2 of SEQ ID NO:45, heavy chain CDR3 of SEQ ID NO:47, light chain CDR1 of SEQ ID NO:85, light chain CDR2 of SEQ ID NO:87, and light chain CDR3 of SEQ ID NO:89;

(d) heavy chain CDR1 of SEQ ID NO:49, heavy chain CDR2 of SEQ ID NO:51, heavy chain CDR3 of SEQ ID NO:53, light chain CDR1 of SEQ ID NO:91, light chain CDR2 of SEQ ID NO:93, and light chain CDR3 of SEQ ID NO:95;

(e) heavy chain CDR1 of SEQ ID NO:55, heavy chain CDR2 of SEQ ID NO:57, heavy chain CDR3 of SEQ ID NO:59, light chain CDR1 of SEQ ID NO:97, light chain CDR2 of SEQ ID NO:99, and light chain CDR3 of SEQ ID NO:101;

(f) heavy chain CDR1 of SEQ ID NO:61, heavy chain CDR2 of SEQ ID NO:63, heavy chain CDR3 of SEQ ID NO:65, light chain CDR1 of SEQ ID NO:103, light chain CDR2 of SEQ ID NO:105, and light chain CDR3 of SEQ ID NO:107;

(g) heavy chain CDR1 of SEQ ID NO:67, heavy chain CDR2 of SEQ ID NO:69, heavy chain CDR3 of SEQ ID NO:71, light chain CDR1 of SEQ ID NO:109, light chain CDR2 of SEQ ID NO:111, and light chain CDR3 of SEQ ID NO:113; or

(h) heavy chain CDR1 of SEQ ID NO:43, heavy chain CDR2 of SEQ ID NO:45 or a sequence that differs from SEQ ID NO:45 in an I51V substitution, heavy chain CDR3 of SEQ ID NO:47, light chain CDR1 of SEQ ID NO:85, light chain CDR2 of SEQ ID NO:87 or a sequence that differs from SEQ ID NO:87 in a S52G substitution, and light chain CDR3 of SEQ ID NO:89 or a sequence that differs from SEQ ID NO:89 in a N95I substitution.

2. A recombinant vector comprising the nucleic acid molecule of claim 1 .

3. The isolated nucleic acid molecule of claim 1 , wherein the encoded human antibody agent comprises:

(i) a heavy chain variable region having a sequence at least 95% identical to a heavy chain variable region sequence as set forth in any one of SEQ ID NOs: 5, 9, 13, 17, 21, 25, and 29, and

(ii) a light chain variable region having a sequence at least 95% identical to a light chain variable region sequence as set forth in any one of SEQ ID NOs: 3, 7, 11, 15, 19, 23, and 27.

4. The isolated nucleic acid molecule of claim 1 , wherein the encoded human antibody agent comprises:

(i) a heavy chain variable region comprising a sequence as set forth in any one of SEQ ID NOs: 5, 9, 13, 17, 21, 25, and 29, and

(ii) a light chain variable region comprising a sequence as set forth in any one of SEQ ID NOs: 3, 7, 11, 15, 19, 23, and 27.

5. The isolated nucleic acid molecule of claim 1 , wherein the encoded human antibody agent comprises:

(a) a light chain variable region as set forth in SEQ ID NO:3 and a heavy chain variable region as set forth in SEQ ID NO:5;

(b) a light chain variable region as set forth in SEQ ID NO:7 and a heavy chain variable region as set forth in SEQ ID NO:9;

(c) a light chain variable region as set forth in SEQ ID NO:11 and a heavy chain variable region as set forth in SEQ ID NO:13;

(d) a light chain variable region as set forth in SEQ ID NO:15 and a heavy chain variable region as set forth in SEQ ID NO:17;

(e) a light chain variable region as set forth in SEQ ID NO:19 and a heavy chain variable region as set forth in SEQ ID NO:21;

(f) a light chain variable region as set forth in SEQ ID NO:23 and a heavy chain variable region as set forth in SEQ ID NO:25; or

(g) a light chain variable region as set forth in SEQ ID NO:27 and a heavy chain variable region as set forth in SEQ ID NO:29.

6. The isolated nucleic acid molecule of claim 1 , wherein the encoded human antibody agent comprises:

(i) heavy chain CDR1 of SEQ ID NO:43, heavy chain CDR2 of SEQ ID NO:45 or a sequence that differs from SEQ ID NO:45 in an I51V substitution, and heavy chain CDR3 of SEQ ID NO:47; and

(ii) light chain CDR1 of SEQ ID NO:85, light chain CDR2 of SEQ ID NO:87 or a sequence that differs from SEQ ID NO:87 in a S52G substitution, and light chain CDR3 of SEQ ID NO:89 or a sequence that differs from SEQ ID NO:89 in a N95I substitution.

7. The isolated nucleic acid molecule of claim 1 , wherein the encoded human antibody agent comprises:

(i) a light chain variable region sequence that comprises a sequence of SEQ ID NO: 11 or a sequence that differs from SEQ ID NO:11 in one or more amino acid substitutions selected from I48V, S52G, P55H, K66R and N95I; and

(ii) a heavy chain variable region that comprises a sequence of SEQ ID NO: 13 or a sequence that differs from SEQ ID NO:13 in one or more amino acid substitutions selected from V5E, E10D, G26E, I51V and V78A.

8. The isolated nucleic acid molecule of claim 1 , wherein the encoded human antibody agent comprises:

(i) a light chain variable region having a sequence at least 95% identical to a light chain variable region sequence as set forth in SEQ ID NO:11; and

(ii) a heavy chain variable region having a sequence at least 95% identical to a heavy chain variable region sequence as set forth in SEQ ID NO:13.

9. The isolated nucleic acid molecule of claim 1 , wherein the encoded human antibody agent comprises:

(i) a light chain variable region having a sequence as set forth in SEQ ID NO:11; and

(ii) a heavy chain variable region having a sequence as set forth in SEQ ID NO:13.

10. The isolated nucleic acid molecule of claim 1 , wherein the CDR sequences of the encoded human antibody agent comprise DNA sequences as set forth in:

(a) SEQ ID NOs: 30, 32, 34, 72, 74, and 76;

(b) SEQ ID NOs: 36, 38, 40, 78, 80, and 82;

(c) SEQ ID NOs: 42, 44, 46, 84, 86, and 88;

(d) SEQ ID NOs: 48, 50, 52, 90, 92, and 94;

(e) SEQ ID NOs: 54, 56, 58, 96, 98, and 100;

(f) SEQ ID NOs: 60, 62, 64, 102, 104, and 106; or

(g) SEQ ID NOs: 66, 68, 70, 108, 110, and 112.

11. The isolated nucleic acid molecule of claim 1 , comprising:

(i) a human heavy chain variable region that comprises a DNA sequence that is at least 95% identical to a sequence set forth in any one of SEQ ID NOs: 4, 8, 12, 16, 20, 24, and 28; and

(ii) a human light chain variable region that comprises a DNA sequence that is at least 95% identical to a sequence set forth in any one of SEQ ID NOs: 2, 6, 10, 14, 18, 22, and 26.

12. The isolated nucleic acid molecule of claim 1 , comprising:

(a) a human heavy chain variable region that comprises a DNA sequence as set forth in any one of SEQ ID NOs: 4, 8, 12, 16, 20, 24, and 28; and

(b) a human light chain variable region that comprises a DNA sequence as set forth in any one of SEQ ID NOs: 2, 6, 10, 14, 18, 22, and 26.

13. The isolated nucleic acid molecule of claim 1 , comprising:

(a) a light chain variable region comprising a DNA sequence as set forth in SEQ ID NO:2 and a heavy chain variable region comprising a DNA sequence as set forth in SEQ ID NO:4;

(b) a light chain variable region comprising a DNA sequence as set forth in SEQ ID NO:6 and a heavy chain variable region comprising a DNA sequence as set forth in SEQ ID NO:8;

(c) a light chain variable region comprising a DNA sequence as set forth in SEQ ID NO:10 and a heavy chain variable region comprising a DNA sequence as set forth in SEQ ID NO:12;

(d) a light chain variable region comprising a DNA sequence as set forth in SEQ ID NO:14 and a heavy chain variable region comprising a DNA sequence as set forth in SEQ ID NO:16;

(e) a light chain variable region comprising a DNA sequence as set forth in SEQ ID NO:18 and a heavy chain variable region comprising a DNA sequence as set forth in SEQ ID NO:20;

(f) a light chain variable region comprising a DNA sequence as set forth in SEQ ID NO:22 and a heavy chain variable region comprising a DNA sequence as set forth in SEQ ID NO:24; or

(g) a light chain variable region comprising a DNA sequence as set forth in SEQ ID NO:26 and a heavy chain variable region comprising a DNA sequence as set forth in SEQ ID NO:28.

14. A recombinant vector comprising the nucleic acid molecule of claim 4 .

15. A recombinant vector comprising the nucleic acid molecule of claim 6 .

16. A recombinant vector comprising the nucleic acid molecule of claim 13 .

Assignments (3)
CONFIRMATORY LICENSE Recorded Aug 2, 2022
From: SLOAN-KETTERING INST CAN RESEARCH
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 061053/0206 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2019
From: CHEUNG, NAI-KONG V.; AHMED, MAHIUDDIN; LOPEZ-ALBAITERO, ANDRES
To: MEMORIAL SLOAN KETTERING CANCER CENTER
Reel/Frame 051175/0097 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2019
From: LIU, CHENG; LIU, HONG; XIANG, JINGYI; YAN, SU
To: EUREKA THERAPEUTICS, INC.
Reel/Frame 051175/0130 →
Continuity (3)
Division 15735133
Provisional Application 62173330 · Jun 9, 2015
Related Publication 20200115470A1 · Apr 16, 2020